Retatrutide is an investigational medicine being developed for metabolic conditions such as obesity and type 2 diabetes. It is designed to activate three hormone receptors—GIP, GLP-1, and glucagon—which influence appetite, blood sugar regulation, and energy metabolism. Researchers are evaluating its ability to promote substantial weight loss and enhance overall metabolic health. Because retatrutide is still undergoing clinical development, its safety, effectiveness, and long-term benefits continue to be evaluated.